Table 2.
Presence of CAN versus yearly change in eGFR (mL/min/1.73 m2) and UACR (%)
| N | Outcomes | Estimate (95% CI) | P value | |
| Model 1 | 220 | UACR | 9.905 (3.04 to 17.23) | 0.004 |
| 224 | eGFR | −0.263 (−0.98 to 0.45) | 0.469 | |
| Model 2 | 220 | UACR | 11.820 (4.95 to 19.14) | 0.001 |
| 224 | eGFR | −0.138 (−0.850 to 0.57) | 0.703 | |
| Model 3 | 219 | UACR | 11.241 (4.06 to 18.92) | 0.002 |
| 223 | eGFR | 0.328 (−0.38 to 1.04) | 0.366 | |
| Model 4 | 217 | UACR | 7.484 (0.45 to 15.01) | 0.037 |
| 222 | eGFR | 0.294 (−0.461 to 1.05) | 0.445 | |
| Model 5 | 194 | UACR | 7.800 (0.50 to 15.63) | 0.036 |
| 193 | eGFR | 0.324 (−0.486 to 1.13) | 0.433 | |
| Model 6 | 167 | UACR | 7.664 (−0.093 to 16.02) | 0.052 |
| 165 | eGFR | 0.272 (−0.558 to 1.103) | 0.520 |
Model 1: unadjusted. Model 2: adjusted for age and sex. Model 3: as model 2 and additionally adjusted for duration of diabetes, Hba1c, BMI, smoking, exercise, beta-blocker use, LDL cholesterol and systolic blood pressure. Model 4: as model 3, and additionally adjusted for baseline eGFR. Model 5: as model 4 and additionally adjusted for urinary albumin excretion rate.
BMI, body mass index; CAN, cardiovascular autonomic neuropathy; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; UACR, urine albumin to creatinine ratio.